{"id":3111,"date":"2023-04-04T15:53:54","date_gmt":"2023-04-04T20:53:54","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=3111"},"modified":"2023-04-04T15:58:18","modified_gmt":"2023-04-04T20:58:18","slug":"saliva-antibody-fingerprint-of-reactivated-latent-viruses-after-mild-asymptomatic-covid-19-is-unique-in-patients-with-myalgic-encephalomyelitis-chronic-fatigue-syndrome-2","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2023\/04\/04\/saliva-antibody-fingerprint-of-reactivated-latent-viruses-after-mild-asymptomatic-covid-19-is-unique-in-patients-with-myalgic-encephalomyelitis-chronic-fatigue-syndrome-2\/","title":{"rendered":"Saliva antibody-fingerprint of reactivated latent viruses after mild\/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis\/chronic fatigue syndrome"},"content":{"rendered":"
\n

Frontiers in Immunology<\/a> <\/p>\n\n\n\n

Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) is a chronic disease considered to be triggered by viral infections in a majority of cases. Symptoms overlap largely with those of post-acute sequelae of COVID-19\/long-COVID implying common pathogenetic mechanisms. SARS-CoV-2 infection is risk factor for sustained latent virus reactivation that may account for the symptoms of post-viral fatigue syndromes. The aim of this study was first to investigate whether patients with ME\/CFS and healthy donors (HDs) differed in their antibody response to mild\/asymptomatic SARS-CoV-2 infection. Secondly, to analyze whether COVID-19 imposes latent virus reactivation in the cohorts.<\/p>\n\n\n\n

Methods:<\/strong> Anti-SARS-CoV-2 antibodies were analyzed in plasma and saliva from non-vaccinated ME\/CFS (n=95) and HDs (n=110) using soluble multiplex immunoassay. Reactivation of human herpesviruses 1-6 (HSV1, HSV2, VZV, EBV, CMV, HHV6), and human endogenous retrovirus K (HERV-K) was detected by anti-viral antibody fingerprints in saliva.<\/p>\n\n\n\n

Results:<\/strong> At 3-6 months after mild\/asymptomatic SARS-CoV-2 infection, virus-specific antibodies in saliva were substantially induced signifying a strong reactivation of latent viruses (EBV, HHV6 and HERV-K) in both cohorts. In patients with ME\/CFS, antibody responses were significantly stronger, in particular EBV-encoded nuclear antigen-1 (EBNA1) IgG were elevated in patients with ME\/CFS, but not in HDs. EBV-VCA IgG was also elevated at baseline prior to SARS-infection in patients compared to HDs.<\/p>\n\n\n\n

Conclusion:<\/strong> Our results denote an altered and chronically aroused anti-viral profile against latent viruses in ME\/CFS. SARS-CoV-2 infection even in its mild\/asymptomatic form is a potent trigger for reactivation of latent herpesviruses (EBV, HHV6) and endogenous retroviruses (HERV-K), as detected by antibody fingerprints locally in the oral mucosa (saliva samples). This has not been shown before because the antibody elevation is not detected systemically in the circulation\/plasma.<\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"

Frontiers in Immunology Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) is a chronic disease considered to be triggered by viral infections in a majority of cases. Symptoms overlap largely with those of post-acute sequelae of COVID-19\/long-COVID implying common pathogenetic mechanisms. SARS-CoV-2 infection is risk factor for sustained latent virus reactivation that may account for the symptoms of […]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[16],"tags":[],"class_list":["post-3111","post","type-post","status-publish","format-standard","hentry","category-published-research"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=3111"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3111\/revisions"}],"predecessor-version":[{"id":3112,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/3111\/revisions\/3112"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=3111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=3111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=3111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}